Waldenström macroglobulinemia/Lymphoplasmacytic lymphoma
Waldenström macroglobulinemia/Lymphoplasmacytic lymphoma
Also known as:WM; LPL; China Second Rare Disease Catalog item 85
Waldenström macroglobulinemia is a rare indolent B-cell lymphoma in which lymphoplasmacytic cells in bone marrow produce excess IgM, causing anemia, infection, bleeding, neuropathy, or hyperviscosity.
Start Here
A quick guide to the next step: which department to start with, what to prepare, and what to ask.
IgM monoclonal protein, unexplained anemia, very high ESR, recurrent infections, bleeding, blurred vision, headache, numbness, or hyperviscosity symptoms should be assessed by hematology/lymphoma specialists.
WM/LPL often grows slowly. Some people only have an IgM monoclonal protein and are monitored. Treatment is usually needed for anemia, symptomatic hyperviscosity, neuropathy, lymph node or spleen enlargement, kidney disease, or cryoglobulin-related problems.
Asymptomatic patients may not need immediate treatment. When treatment is needed, options include rituximab-based therapy, BTK inhibitors, proteasome inhibitor regimens, and urgent plasma exchange for hyperviscosity.
It is usually not inherited in a simple pattern. Some families show clustering of related blood disorders, but relatives are not routinely screened as for a genetic disease.
Early disease may be silent or look like fatigue and anemia. Without serum protein electrophoresis, IgM measurement, and marrow evaluation, diagnosis may be missed.
This page helps patients and families organize care leads. It does not replace a clinician’s diagnosis or treatment plan. For testing, medication, referrals, emergency care, and support applications, follow qualified clinicians, medical institutions, support organizations, and official sources.
Diagnosis Path
Organized around the practical patient journey: identify clues, avoid common delays, then prepare for care.
When to Suspect It
- Unexplained anemia, fatigue, weight loss, night sweats, recurrent infections, lymph nodes, or enlarged spleen.
- IgM monoclonal protein, high serum viscosity, headache, blurred vision, gum/nose bleeding, or confusion.
- Numbness or pain in feet/hands, cold-induced color change, kidney abnormalities, cryoglobulin, or cold agglutinin features.
Common Wrong Turns
- Treating one organ or one episode without connecting the long-term pattern, family history, and prior results.
- Watching common-disease explanations for too long without referral to the right specialty or rare disease clinic.
- Not keeping imaging, pathology, genetic, treatment, and follow-up records, leading to repeated workups and delays.
Departments to Start With
- Hematology
- Lymphoma/plasma cell disorder clinic
- Emergency department for hyperviscosity symptoms
- Neurology or nephrology as complications require
Before the Visit
- Bring CBC, IgM level, serum protein electrophoresis/immunofixation, free light chains, and serum viscosity.
- Bring marrow aspirate/biopsy, flow cytometry, MYD88/CXCR4 testing, imaging, and infection or bleeding history.
- Record headache, vision change, bleeding, neuropathy, B symptoms, and medicines.
Tests to Ask About
- Whether this is IgM MGUS, asymptomatic WM, or symptomatic WM requiring treatment.
- Need for MYD88 L265P, CXCR4, beta-2 microglobulin, serum viscosity, and organ involvement testing.
- Whether rituximab could cause IgM flare and whether plasma exchange is needed first.
Questions for the Doctor
- Do I need treatment now or watchful waiting, and what exact findings would trigger treatment?
- Which regimen best balances response, infection risk, neuropathy, and quality of life for me?
- Which hyperviscosity symptoms mean immediate emergency care?
Basic Information
Medical Notes
More complete medical explanations are kept here for discussion with clinicians.
Symptoms
WM can be asymptomatic for years. Symptoms may include anemia-related fatigue or shortness of breath, recurrent infections, enlarged lymph nodes or spleen, weight loss, night sweats, bleeding, and IgM-related hyperviscosity with headache, dizziness, blurred vision, nose or gum bleeding, or confusion.
IgM can also cause peripheral neuropathy, cryoglobulinemia, cold agglutinin disease, kidney involvement, or amyloidosis-related problems.
Diagnosis
Diagnosis shows IgM monoclonal protein plus bone marrow lymphoplasmacytic infiltration, supported by immunophenotyping, serum protein electrophoresis/immunofixation, IgM quantification, marrow biopsy, and often MYD88 L265P and CXCR4 testing.
Clinicians distinguish IgM MGUS, multiple myeloma, marginal zone lymphoma, chronic lymphocytic leukemia, and other small B-cell lymphomas.
Treatment
Asymptomatic WM is not treated just because it is diagnosed; it is monitored. Treatment indications include symptomatic anemia, hyperviscosity, organ involvement, significant B symptoms, neuropathy, or cryoglobulin-related disease.
Options include rituximab-based chemoimmunotherapy, BTK inhibitors, proteasome inhibitor regimens, and others. Hyperviscosity is an emergency usually treated first with plasma exchange, followed by lymphoma-directed therapy.
Long-term Care
Follow-up tracks CBC, IgM, M protein, kidney function, infection risk, vaccines, neuropathy, serum viscosity, and treatment side effects. Watchful waiting should still have a clear visit schedule and treatment triggers.
Patients should carry their WM diagnosis and seek urgent care for hyperviscosity symptoms instead of waiting for routine follow-up.
Fertility and Family
WM is usually not inherited, and family screening is not routine. Before chemotherapy or long-term targeted treatment, discuss fertility preservation when relevant, infection prevention, and vaccination.
When to Seek Urgent Care
Urgent care is needed for blurred vision, severe headache, confusion, chest tightness or shortness of breath, persistent nose or gum bleeding, black stools or vomiting blood, fever or chills, or severe anemia symptoms, especially when hyperviscosity is possible.
Prognosis
Many cases are slow-growing and manageable long term; hyperviscosity, infection, anemia, neuropathy, and treatment side effects require follow-up.